Show simple item record

dc.contributor.authorBallinger, MLen_US
dc.contributor.authorBest, Aen_US
dc.contributor.authorMai, PLen_US
dc.contributor.authorKhincha, PPen_US
dc.contributor.authorLoud, JTen_US
dc.contributor.authorPeters, JAen_US
dc.contributor.authorAchatz, MIen_US
dc.contributor.authorChojniak, Ren_US
dc.contributor.authorBalieiro da Costa, Aen_US
dc.contributor.authorSantiago, KMen_US
dc.contributor.authorGarber, Jen_US
dc.contributor.authorO'Neill, AFen_US
dc.contributor.authorEeles, RAen_US
dc.contributor.authorEvans, DGen_US
dc.contributor.authorBleiker, Een_US
dc.contributor.authorSonke, GSen_US
dc.contributor.authorRuijs, Men_US
dc.contributor.authorLoo, Cen_US
dc.contributor.authorSchiffman, Jen_US
dc.contributor.authorNaumer, Aen_US
dc.contributor.authorKohlmann, Wen_US
dc.contributor.authorStrong, LCen_US
dc.contributor.authorBojadzieva, Jen_US
dc.contributor.authorMalkin, Den_US
dc.contributor.authorRednam, SPen_US
dc.contributor.authorStoffel, EMen_US
dc.contributor.authorKoeppe, Een_US
dc.contributor.authorWeitzel, JNen_US
dc.contributor.authorSlavin, TPen_US
dc.contributor.authorNehoray, Ben_US
dc.contributor.authorRobson, Men_US
dc.contributor.authorWalsh, Men_US
dc.contributor.authorManelli, Len_US
dc.contributor.authorVillani, Aen_US
dc.contributor.authorThomas, DMen_US
dc.contributor.authorSavage, SAen_US
dc.coverage.spatialUnited Statesen_US
dc.date.accessioned2017-11-17T09:43:58Z
dc.date.issued2017-12-01en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/28772291en_US
dc.identifier2646798en_US
dc.identifier.citationJAMA Oncol, 2017, 3 (12), pp. 1634 - 1639en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/909
dc.identifier.eissn2374-2445en_US
dc.identifier.doi10.1001/jamaoncol.2017.1968en_US
dc.description.abstractImportance: Guidelines for clinical management in Li-Fraumeni syndrome, a multiple-organ cancer predisposition condition, are limited. Whole-body magnetic resonance imaging (WBMRI) may play a role in surveillance of this high-risk population. Objective: To assess the clinical utility of WBMRI in germline TP53 mutation carriers at baseline. Data Sources: Clinical and research surveillance cohorts were identified through the Li-Fraumeni Exploration Research Consortium. Study Selection: Cohorts that incorporated WBMRI for individuals with germline TP53 mutations from January 1, 2004, through October 1, 2016, were included. Data Extraction and Synthesis: Data were extracted by investigators from each cohort independently and synthesized by 2 investigators. Random-effects meta-analysis methods were used to estimate proportions. Main Outcomes and Measures: The proportions of participants at baseline in whom a lesion was detected that required follow-up and in whom a new primary malignant neoplasm was detected. Results: A total of 578 participants (376 female [65.1%] and 202 male [34.9%]; mean [SD] age, 33.2 [17.1] years) from 13 cohorts in 6 countries were included in the analysis. Two hundred twenty-five lesions requiring clinical follow-up were detected by WBMRI in 173 participants. Sixty-one lesions were diagnosed in 54 individuals as benign or malignant neoplasms. Overall, 42 cancers were identified in 39 individuals, with 35 new localized cancers treated with curative intent. The overall estimated detection rate for new, localized primary cancers was 7% (95% CI, 5%-9%). Conclusions and Relevance: These data suggest clinical utility of baseline WBMRI in TP53 germline mutation carriers and may form an integral part of baseline clinical risk management in this high-risk population.en_US
dc.format.extent1634 - 1639en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://www.rioxx.net/licenses/under-embargo-all-rights-reserveden_US
dc.subjectAdolescenten_US
dc.subjectAdulten_US
dc.subjectDiagnosis, Differentialen_US
dc.subjectEarly Detection of Canceren_US
dc.subjectFemaleen_US
dc.subjectHumansen_US
dc.subjectLi-Fraumeni Syndromeen_US
dc.subjectMagnetic Resonance Imagingen_US
dc.subjectMaleen_US
dc.subjectMiddle Ageden_US
dc.subjectMutationen_US
dc.subjectPopulation Surveillanceen_US
dc.subjectPractice Guidelines as Topicen_US
dc.subjectTumor Suppressor Protein p53en_US
dc.subjectWhole Body Imagingen_US
dc.subjectYoung Adulten_US
dc.titleBaseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis.en_US
dc.typeJournal Article
dcterms.dateAccepted2017-05-15en_US
rioxxterms.funderThe Institute of Cancer Researchen_US
rioxxterms.identifier.projectUnspecifieden_US
rioxxterms.versionofrecord10.1001/jamaoncol.2017.1968en_US
rioxxterms.licenseref.startdate2017-12-01en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfJAMA Oncolen_US
pubs.declined2017-11-01T12:14:18.186+0000
pubs.issue12en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Oncogenetics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Oncogenetics
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume3en_US
pubs.embargo.termsNot knownen_US
icr.researchteamOncogeneticsen_US
dc.contributor.icrauthorEeles, Rosalinden_US
dc.contributor.icrauthorMarsden,en_US
rioxxterms.funder.project354849bd-c553-4e22-868c-8c503e124155en_US


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record